137 results about "Cirrhotic liver" patented technology

This inventions relates to compounds having the structure Formula Iand pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

The present invention comprises methods and compositions for the treatment or alleviation of NAFLD (non-alcoholic fatty liver disease) and those conditions associated with NAFLD, including fatty liver disease, nonalcoholic steatohepatitis (NASH) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and / or polypeptides. This invention is also directed to a combination therapy treatment for treating The Metabolic Syndrome. As part of a combination therapy regime for the treatment of The Metabolic Syndrome, pharmaceutical formulations of lysosomal acid lipase or related proteins and / or polypeptides are used as part of the combination therapy regime for treating NAFLD (and NASH), which comprises one of the conditions constituting The Metabolic Syndrome,

The invention relates to a preparation method and application of a sulfonylurea compound and a composition containing the same component as FXR and / or TGR5 agonist, the FXR and / or TGR5 agonist is a compound shown as a formula (I), or a pharmaceutically acceptable salt, a solvate, a prodrug, an isomer and a stable isotope derivative thereof. The compounds can be used for treatment of FXR and / or TGR5 mediated diseases including primary biliary cirrhosis, nonalcoholic fatty liver, portal hypertension, bile acid diarrhea and cholestasis, type II diabetes and obesity and other field.

The invention provides a group of biomarkers which can be used for detecting liver fibrosis and cirrhosis. The biomarkers refer to metabolite components existing in a biological sample of a subject body and comprise a plurality of metabolites, wherein the metabolites are selected from cholic acid, amino acid and fatty acid. Metabolite combination comprises at least one amino acid, fatty acid and cholic acid, the metabolite combination is differentially expressed in at least one target plasma or serum and in a control plasma or serum. The biomarkers can optionally be combined with clinical indicators for diagnosis of liver fibrosis in the subject body. The biomarker composition has the characteristics of high sensitivity and specificity for pathological staging diagnosis of liver fibrosis patients, and can be clinically applied as a non-invasive means to improve clinical diagnosis and reduce puncture pain of the patients. The invention further provides a use method of the biomarkers andkits containing the biomarkers.

The present invention relates to kinase modulators of the naphthyridine type and to the preparation and use thereof as medicaments for the modulation of misdirected cellular signal transduction processes, in particular for influencing the function of tyrosine and serine / threonine kinases and for the treatment of malignant or benign tumours and other disorders based on pathological cell proliferation, such as, for example, restenosis, psoriasis, arteriosclerosis and cirrhosis of the liver.

By means of a proteomic approach, the markers of hepatocellular carcinoma (HCC) in the liver of a knockout mouse (MAT1A− / −) have been identified for the MAT1A gene (deficient in the synthesis of S-adenosylmethionine). 27 proteins have been detected the expression thereof is altered in, at least, 50% of the analysed tumours. Amongst them, 13 proteins have been validated in biopsies of patients with HCC of different etiology, and 7 of them have been validated in biopsies of patients with liver cirrhosis, a stage prior to the development of HCC, which makes it possible to differentiate between prior stages of the disease and even between different etiologies (viral and alcoholic). Having a panel of markers available may contribute to more accurately defining the alterations associated with the development of HCC and thus facilitate prognosis and diagnosis of this disease.

The present invention is concerned with deuterium-enriched pyrimidine compounds of formula I, their derivatives, enantiomers, diastereomers, solvates and pharmaceutical salts thereof,and their uses in the treatment, prevention and modulation of various diseases including chronic liver diseases, liver cirrhosis, liver fibrosis, hepatocellular carcinoma, liver cancer, renal cell carcinoma, kidney cancer, colorectal cancer, brain cancer, breast cancer, blood cancer, lung cancer, thyroid cancer, ovarian cancer, pancreas cancer, prostate cancer, stomach cancer, testicular cancer, uterus cancer, intestinal cancer, skin cancer, and other forms of cancer, carcinoid tumors, teratocarcinoma, tumor progression, metastasis and fibrosis in the neuroendocrine neoplasia, fibrotic processes as well as a disease state modulated directly or indirectly with 5-HT receptors, 5-HT1, 5-HT1A, 5-HT2 receptors, 5-HT2A and 5-HT2B receptors, dopamine receptors and multiple kinase pathways.

The invention relates to a preparation method for extracting an effective part from traditional Chinese medicine radix bupleuri and an application of the effective part obtained by utilizing the method and a preparation thereof in medicines for preventing and treating liver fibrosis, hepatocirrhosis, chronic hepatitis and the like. The preparation of the effective part of the radix bupleuri can be granules, soft capsules, capsules, dripping pills, tablets, dispersing tablets, effervescence tablets, injection and the like. The invention has simple operation method and utilizes a modern medicine effect sieving technology, an extracting and purifying technology, a preparation technology and a quality control technology to carry out deep development on the radix bupleuri preparation; the effective part of the radix bupleuri and the preparation thereof obtained by utilizing the technological method of the invention are rich in active components, have definite effective components, obvious pharmacological action, obviously enhanced medicine effect, stable performance, controllable quality, safety, reliability and small dose and are beneficial to the transportation and storage of the medicine and the taking of a patient.

Pro-apoptotic agents such as ligands and agonists of agonistic TRAIL receptors can induce or increase apoptosis of cells that cause fibrosis and underlying diseases such as liver, pancreatic, lung and skin diseases characterized by fibrosis, cirrhosis, or complications thereof. The compositions and methods can be used to selectively remove activated hepatic stellate cells (HSCs), the originators of liver fibrosis and cirrhosis, and activated pancreatic stellate cells (PSCs), the originators of pancreas fibrosis and pancreatitis, and can be effective to reduce or prevent further chronic fibrosis by simultaneously reducing multiple fibrosis-associated molecules secreted or induced by such activated stellate cells. The compositions are typically effective to target agonistic TRAIL receptors such as TRAIL-R1 / DR4 and TRAIL-R2 / DR5 that are selectively expressed in activated HSCs and PSCs in physiological conditions. Ligands and agonists that can be used to target agonistic TRAIL receptors include, but are not limited to, TRAIL-R1 / DR4 and / or TRAIL-R2 / DR5 agonists.

Pro-apoptotic agents such as ligands and agonists of agonistic TRAIL receptors can induce or increase apoptosis of cells that cause fibrosis and underlying diseases such as liver, pancreatic, lung and skin diseases characterized by fibrosis, cirrhosis, or complications thereof. The compositions and methods can be used to selectively remove activated hepatic stellate cells (HSCs), the originators of liver fibrosis and cirrhosis, and activated pancreatic stellate cells (PSCs), the originators of pancreas fibrosis and pancreatitis, and can be effective to reduce or prevent further chronic fibrosis by simultaneously reducing multiple fibrosis-associated molecules secreted or induced by such activated stellate cells. The compositions are typically effective to target agonistic TRAIL receptors such as TRAIL-R1 / DR4 and TRAIL-R2 / DR5 that are selectively expressed in activated HSCs and PSCs in physiological conditions. Ligands and agonists that can be used to target agonistic TRAIL receptors include, but are not limited to, TRAIL-R1 / DR4 and / or TRAIL-R2 / DR5 agonists.

The invention belongs to the field of marine drugs, and in particular relates to an application of oligoguluronates in preparation of drugs for prevention and treatment of liver damage and various hepatitis, liver fibrosis or cirrhosis. The oligoguluronates are used in preparation of the drugs for protection of livers and treatment of various hepatitis, liver fibrosis or cirrhosis; the oligoguluronates adopt algin as a raw material, and oligoguluronic acids with different molecular weights are obtained through a chemical degradation method or a physical degradation or a combination of the two degradation methods; the oligoguluronic acids are neutralized to prepare lithium salts, sodium salts, potassium salts, calcium salts or magnesium salts of the oligoguluronic acids with different molecular weights, wherein a molecular skeleton is a linear oligosaccharide compound formed by connecting L-guluronic acid (G) through alpha-(1,4)-glycosidic bonds. The products are derived from the marine natural product, have many advantages of abundant resources, easy industrialization, safety, effectivity and the like, and have broad development and application prospects in prevention and treatment of liver damage and various hepatitis, liver fibrosis or cirrhosis.

The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and / or statin). Also disclosed is use of the combination for the treatment or prevention of a FXR mediated disease or condition, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), portal hypertension, bile acid diarrhea, NAFLD (nonalcoholic fatty liver disease), NASH (non-alcohol-induced steatohepatitis), and other chronic liver diseases. The combination of the present invention is useful for the treatment or prevention of conditions related to elevated lipid and liver enzyme levels. The present invention also relates to packs or kits including the pharmaceutical combination.

The invention relates to the technical field of medicines. Chalcone is a natural component in plants and has antibiotic and antifungal effects, and derivatives of the chalcone also have the effect of resisting tumors and the like. At present, no document is reported that the derivatives of the chalcone have the effect of reducing activity of blood fat and protecting the liver. The invention provides derivatives of the dihydrochalcone having a general formula I. Through tests of reducing blood fat, the results show that the derivatives of the dihydrochalcone have the effects of obviously reducing serum total cholesterol and low-density lipoprotein cholesterol, and can be used to prepare medicines or health products for reducing blood fat, preventing and treating hyperlipoidemia, fatty liver, hepatocirrhosis and atherosclerosis and protecting the liver.

The invention belongs to the field of biotechnology, and relates to an experimental animal model for transforming nonalcoholic steatohepatitis into liver cancer. In particular, a large and mouse model of nonalcoholic chronic steatohepatitis (NASH) and chronic steatohepatitis developing into chronic liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) can be used for chronic fatty Liver, steatohepatitis, liver fibrosis, liver cirrhosis, hepatocellular carcinoma, metabolic diseases, diabetes, in vivo experiments of related mechanisms of diabetic complications, new drug development, and non-alcoholic steatohepatitis (NASH), liver It has extremely high application value in the study of the pathogenesis of fibrosis and liver cancer and in drug development.

A Chinese medicine in the form of orally taken solid or liquid for treating viral hepatitis, chemical liver injury, fatty liver and hepatocirrhosis is prepared from 7 Chinese-medicinal materials including phylianthus urinaria, astragalus root, white atractylodes rhizome, notoginseng, etc.

The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Plasma from patients with hepatic cirrhosis induced by infection with the hepatitis C virus (HCV) were analysed. Several proteins associated with liver scarring and potentially also related to viral infection were identified. These proteins include 14-3-3 protein zeta / delta, adiponectin, afamin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, apolipoprotein C-III, apolipoprotein E, C4b-binding protein beta chain, intact / cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, hemopexin, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase / arylesterase 1, sex hormone-binding globulin and zinc-alpha-2-glycoprotein. These biomarkers can be used in conjunction with polypeptides in WO / 2008 / 031051. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed. The additive result from the scores of all the novel biomarkers would give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers.

The invention relates to an amphipathic compound of curcumin derivates and polyoxyethylene as well as a preparation method thereof, wherein PEO is polyoxyethylene, and R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 which are independently selected from hydrogen atom, hydroxide radical, phenyl, linear chain or branched chain alkyl group, linear chain or branched chain alkoxy, amidogen, mono-alkylation amidogen, dialkyl amine amidogen, halogen and halogenate alkyl group. The compound has the advantages of good compound stability, good water-solubility, good biocompatibility, low toxic and side effects, high bioavailability, low production cost and the like, and is easy to inject and administrate and the preparation process is simple. In addition, the invention also relates to an application ofthe amphipathic compound of curcumin derivates and polyoxyethylene in preparing the medicaments for resisting fatty liver, hepatic fibrosis and cirrhosis. The amphipathic compound has obvious pharmacology activity of resisting inflammation and hepatic fibrosis, delaying the forming of cirrhosis and reducing blood fat.

The Chinese medicine for treating hepatocirrhosis, hepatitis and liver cancer is prepared with main material, subsidiary material and supplementary material and may be granule or mixture. The main material is polystictus versicolar extractive and the supplementary material is compound Qiupi cream. The medicine has the functions of strengthening body's resistance and eliminating evil, regulating body's inside environment comprehensively. It has excellent curative effect on chronic active hepatitis, sustained AFP positive, and primary liver cancer in stage I and II.

<heading lvl="1">SUMMARY OF THE INVENTION < / heading> The use of gene therapy for the treatment of different kinds of fibrosis in human beings is disclosed. The purpose is the use of "therapeutic2 genes specifically directed to target organs to revert and / or prevent the development of the fibrosis process. The potential application of gene therapy to patients with fibrosis and / or cirrhosis will depend to a large extent on the successful delivery of genes which encode for therapeutic proteins to livers with severe fibrosis and that these genes which encode for proteins human MMP-8 active and latent, MMP-1, MMP-2, MMP-9 and MMP-13; human uPA wild type and / or modified (or its truncated version), the truncated receptor for TGF-beta type II and Smad-7 can be directed by adenovirus and / or other recombinant vectors that cannot transduce (infect) others organs. The recombinant adenoviruses (AdR) are vectors highly efficient for the transduction of therapeutic genes to diverse target cells. We have proved that they can carry genes to cirrhotic livers. The delivery of therapeutic genes through such adenoviral vectors and other recombinant vectors could also be performed using cationic and anionic liposomes (DOTMA). Therefore, we propose the use of this patent to be applied in the same manner to: Renal fibrosis Pulmonary fibrosis Hypertrophic and keloid scars (skin fibrosis), and Other kinds of fibrosis.

The invention relates to a medicament for treating acute and chronic hepatitis and process for preparation, wherein the medicament is prepared from silibinin-N-methylglucamine as the main constituent, and right mxtrix through a predetermined processing combinations. Compared with the existing dosage forms, the drop pill preparation has the advantages of short technological process, low cost of production and quick-effectiveness.

The invention relates to use of hepatocyte nuclear factor-1alpha in treatment of liver disease, particularly to use of hepatocyte nuclear factor-1alpha (HNF1alpha) in treatment of liver fibrosis and cirrhosis. The study of the invention shows that regulation of the expression of HNF1alpha gene can effectively generate an induction effect on the hepatocyte nuclear factor, so as to provide a new means of treatment.

The invention relates to a kind of the lecithin milky beverage. It contains (Wt.% per ton): fresh milk 200-400kg, sugar 40-60kg, asparteme 0.8-1.2kg, dairy stabilizer 4-6kg, citric acid monohydration 2-4kg, llactic acid 1-2Kg,sodium citrate 0.1-0.5Kg,lecithin 0.5-1.5Kg,milk flavor 0.1-0.4Kg,Citrus garadis flavor 0.2-0.4Kg,grapefruit flavor 0.1-0.3Kg,Garcinia mangostana L. flavor 0.1-0.3Kg,remaining water. Such product has the merit both of the nutrition from the milk and the lecithin function. It mainly works on dissolving the cholesterin,antiatherogenic;activation of the cells;activation of the brain enginery,prevention of the senile dementia;being young and long live, protecting your liver function. Alcohol and high cholesterin are two mainly factors to hepar adiposum and hepatocirrhosis, on the contrary, the lecithin can restore the damaged liver cells.

The invention relates to the field of non-invasive measurement, discloses a cirrhotic portal hypertension non-invasive evaluation method based on a 3D multi-channel convolutional neural network, and solves the problems that in the prior art, an invasive measurement method is high in risk, high in cost and high in operation difficulty, and the accuracy of a current clinical non-invasive predictionmodel is still affected by various interference factors. The method comprises the following steps: S1, acquiring a CTA layer sequence image of a patient with liver cirrhosis and portal hypertension ina portal period; S2, preprocessing the CTA layer sequence image; S3, performing segmentation based on the preprocessed CTA layer sequence image to obtain three-dimensional images of the liver, the spleen and the portal vein system; S4, extracting the characteristics of the three-dimensional images of the liver, spleen and portal system by adopting a multi-channel 3D convolutional neural network,and training by taking a measured HVPG grading value of the patient with liver cirrhosis portal hypertension as output to obtain a stable portal hypertension prediction model; and S5, evaluating the portal pressure of the patient through the stable portal high-pressure prediction model.

An application of the redback christmashush root in preparing the medicines for treating chronic hepatitis and hepatocirrhosis is disclosed.

A freeze-dried powder injection for treating acute an chronic hepatitides, hepatocirrhosis and fatty liver is proportionally prepared from methylthio-amino acid, VB1, auxiliary for the freeze-dried powder injection, and the water for injection. Its preparing process is also disclosed.

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid-and-metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.